Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

Findings Support Development for Chronic Pain Indications

LA JOLLA, Calif., Feb. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy male and female subjects when dosed once daily for five consecutive days.

"The successful completion of this Phase I trial demonstrating the safety and tolerability of NGX426 when dosed over multiple days provides support for pursuing a Phase II program in chronic indications," said Ev Graham, Chief Executive Officer of TorreyPines. "Combined with the positive results from our recently completed Phase I study of NGX426 in a capsaicin induced pain model, we are very encouraged about the potential for NGX426 to treat both acute and chronic pain conditions."

The Phase I double-blind, placebo-controlled trial enrolled 20 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily oral doses of either 90 mg or 150 mg of NGX426 or placebo for five consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, NGX426 was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.

NGX426, an ester prodrug, is an oral form of tezampanel, TorreyPines most advanced product candidate. Pharmacokinetic analyses from two Phase I studies confirmed that when given to humans, NGX426 is rapidly converted to tezampanel, the active moiety. To date, six Phase II, double-blind, placebo-controlled trials have demonstrated that tezampanel, administered either subcutaneously or intravenously, was more effective than placebo in relieving pain across migraine, nocic
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ...
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Novel system is the first to use rapid, automated DNA ... ... Inc., a leader in the,development of state of the art ... the United States Patent,and Trademark Office (USPTO) recently issued U.S. ...
... Expression Genetics, Inc.,(EGEN) announced today that ... selected as one of the Top 10 ... strategic partnering. The selection was made by,an ... leading,provider of business information products and services ...
... Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB) (the ... and pharmaceutical raw,materials for use in pharmaceutical, nutraceutical ... announce a Letter of Intent to enter into ... ("Qinba").,Under the proposed terms of this arrangement, Huifeng ...
Cached Biology Technology:eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 2eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 3Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 2Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 3Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd. 2
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its launch in ... of people to eliminate the pain of trying to remember ... their own biometrics fused to their smartphones. To assist people ... Labs , the company that created 1U and focuses on ...
(Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Institute of Marine Science continue to monitor the algal blooms ... few weeks. These "red tides" occur in the lower Bay ... area than in years past, likely due to last winter,s ... by dense blooms of tiny marine plants called algae that ...
... , PROVIDENCE, R.I. [Brown University] Policymakers struggling to ... questions on the scale of millions of people and ... the impact of many potential interventions, alone or in ... 2012 International AIDS Society Conference in Washington, D.C., Brandon ...
... Ethical Treatment of Animals (PETA) Foundation UK has submitted ... the European Chemicals Agency (ECHA) is failing to fulfil ... which animal testing could be avoided under the rules ... in EU institutions and agencies, and PETA maintains that ...
Cached Biology News:Researchers monitor 'red tides' in Chesapeake Bay 2Computers can predict effects of HIV policies 2Computers can predict effects of HIV policies 3PETA files complaint with European ombudsman over animal testing for REACH 2
... Caspase-9 Pan-Caspase In Situ Assay Kit, Fluorescein ... active caspases in cells undergoing apoptosis. The ... for use in diagnostic or therapeutic procedures. ... use a novel approach to detect active ...
... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
... as well as other yeasts, has become ... laboratories. The ability to transform whole cells ... DNAs using lithium based buffers and polyethylene ... library screening easy and reliable, especially when ...
...
Biology Products: